Stem cell-derived extracellular vesicles as senotherapeutics.
Ageing Res Rev
; 99: 102391, 2024 Aug.
Article
en En
| MEDLINE
| ID: mdl-38914266
ABSTRACT
Cellular senescence (CS) is recognized as one of the hallmarks of aging, and an important player in a variety of age-related pathologies. Accumulation of senescent cells can promote a pro-inflammatory and pro-cancerogenic microenvironment. Among potential senotherapeutics are extracellular vesicles (EVs) (40-1000â¯nm), including exosomes (40-150â¯nm), that play an important role in cell-cell communications. Here, we review the most recent studies on the impact of EVs derived from stem cells (MSCs, ESCs, iPSCs) as well as non-stem cells of various types on CS and discuss potential mechanisms responsible for the senotherapeutic effects of EVs. The analysis revealed that (i) EVs derived from stem cells, pluripotent (ESCs, iPSCs) or multipotent (MSCs of various origin), can mitigate the cellular senescence phenotype both in vitro and in vivo; (ii) this effect is presumably senomorphic; (iii) EVs display cross-species activity, without apparent immunogenic responses. In summary, stem cell-derived EVs appear to be promising senotherapeutics, with a feasible application in humans.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Senescencia Celular
/
Vesículas Extracelulares
/
Senoterapéuticos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Ageing Res Rev
Asunto de la revista:
GERIATRIA
Año:
2024
Tipo del documento:
Article